In the rush to get a promising treatment into Phase 1 trials quickly and inexpensively, many companies choose a service provider that only has experience in the formulation. While this approach may help with Phase 1 studies, it may hinder further trials and ultimately slow the transition to late-phase and commercial manufacturing causing delays and mounting expenses. A holistic approach to formulation, process development, and manufacturing is preferable, and using a service provider with a full range of product services can ultimately save time and money. In the below infographic, find some potential Phase 1/IND decisions that can cause bottlenecks as you move through clinical trials and into commercial-scale manufacturing.